Shaila Akter Shetu

Ms. Shaila Akter Shetu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SSShaila Akter Shetu
Shaila Akter Shetu
Debasish BandyopadhyayDebasish Bandyopadhyay
Debasish Bandyopadhyay
Mutations of RAS oncogenes are responsible for about 30% of all human cancer types, including pancreatic, lung, and colorectal cancers. While KRAS1 is a pseudogene, mutation of KRAS2 (commonly known as KRAS oncogene) is directly or indirectly associated with human cancers. Among the RAS family, KRAS is the most abundant oncogene related to uncontrolled cellular proliferation to generate solid tumors in many types of cancer such as pancreatic carcinoma (over 80%), colon carcinoma (40–50%), lung carcinoma (30–50%), and other types of cancer. Once described as ‘undruggable’, RAS proteins have become ‘druggable’, at least to a certain extent, due to the continuous efforts made during the past four decades. In this account, we discuss the chemistry and biology (wherever available) of the small-molecule inhibitors (synthetic, semi-synthetic, and natural) of KRAS proteins that were published in the past decades. Commercial drugs, as well as investigational molecules from preliminary stages to clinical trials, are categorized and discussed in this study. In summary, this study presents an in-depth discussion of RAS proteins, classifies the RAS superfamily, and describes the molecular mechanism of small-molecule RAS inhibitors

Verified
Journal Article
Open access
PDF file
SSShaila Akter Shetu
Shaila Akter Shetu
NJNneoma James
Nneoma James
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Debasish BandyopadhyayDebasish Bandyopadhyay
Debasish Bandyopadhyay
Pancreatic enzymes assist metabolic digestion, and hormones like insulin and glucagon play a critical role in maintaining our blood sugar levels. A malignant pancreas is incapable of doing its regular functions, which results in a health catastrophe. To date, there is no effective biomarker to detect early-stage pancreatic cancer, which makes pancreatic cancer the cancer with the highest mortality rate of all cancer types. Primarily, mutations of the KRAS, CDKN2A, TP53, and SMAD4 genes are responsible for pancreatic cancer, of which mutations of the KRAS gene are present in more than 80% of pancreatic cancer cases. Accordingly, there is a desperate need to develop effective inhibitors of the proteins that are responsible for the proliferation, propagation, regulation, invasion, angiogenesis, and metastasis of pancreatic cancer. This article discusses the effectiveness and mode of action at the molecular level of a wide range of small molecule inhibitors that include pharmaceutically privileged molecules, compounds under clinical trials, and commercial drugs. Both natural and synthetic small molecule inhibitors have been counted. Anti-pancreatic cancer activity and related benefits of using single and combined therapy have been discussed separately. This article sheds light on the scenario, constraints, and future aspects of various small molecule inhibitors for treating pancreatic cancer—the most dreadful cancer so far.


9 May 2022
Verified
Conference Paper
Closed access
SSShaila Shetu
Shaila Shetu
OEOmar Espino
Omar Espino
JRJonathan Rock
Jonathan Rock
DGDaniel Garcia
Daniel Garcia
Debasish BandyopadhyayDebasish Bandyopadhyay
Debasish Bandyopadhyay
SSShaila Akter Shetu
Shaila Akter Shetu

9 May 2022
Verified
Conference Paper
Closed access
SSShaila Shetu
Shaila Shetu
OEOmar Espino
Omar Espino
JRJonathan Rock
Jonathan Rock
DGDaniel Garcia
Daniel Garcia
Debasish BandyopadhyayDebasish Bandyopadhyay
Debasish Bandyopadhyay
SSShaila Akter Shetu
Shaila Akter Shetu